126
Participants
Start Date
March 31, 2017
Primary Completion Date
November 5, 2018
Study Completion Date
June 4, 2021
Dexamethasone
20 mg intravenous (IV) or oral dexamethasone on days 1, 2, 8, 9, 15, 16, 22, and 23 in 28-day cycles.
Carfilzomib
Infusion of IV carfilzomib on days 1, 2, 8, 9, 15 and 16 in each 28-day cycle.
Beijing Chao Yang Hospital, Capital Medical University, Beijing
Peking University Third Hospital, Beijing
Peking Union Medical College Hospital, Beijing
The First Hospital of China Medical University, Shenyang
The First Hospital of Jilin University, Changchun
Shanghai Changzheng Hospital, Shanghai
Zhongshan Hospital Fudan University, Shanghai
The First Affiliated Hospital of Soochow University, Suzhou
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin
Tianjin Medical University General Hospital, Tianjin
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou
Fujian Medical University Union Hospital, Fuzhou
The Central Hospital of Wuhan, Wuhan
Henan Cancer Hospital, Zhengzhou
Sun Yat-Sen University Cancer Center, Guangzhou
Guangzhou First Peoples Hospital, Guangzhou
West China Hospital, Sichuang University, Chengdu
Lead Sponsor
Collaborators (1)
Onyx Therapeutics, Inc.
INDUSTRY
Amgen
INDUSTRY